NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr

/ / News

Shares of AbbVie were down 0.1% in trading on Tuesday after the National Institutes of Health said it is running a mid-stage clinical trial evaluating a monoclonal antibody it developed with the privately held Boehringer Ingelheim in combination with remdesivir as a COVID-19 treatment. Gilead Sciences Inc. received emergency use authorization for remdesivir as a treatment for some severely ill COVID-19 patients earlier this year, and there are several clinical trials underway testing its effectiveness in combination with other therapies. AbbVie and BI’s drug, Skyrizi, received approval from the Food and Drug Administration last year as a treatment for some forms of plaque psoriasis. The NIH also said as part of the Phase, adaptive, randomized, double-blind, placebo-controlled trial it is testing Humanigen Inc.’s experimental monoclonal antibody lenzilumab in combination with remdesivir. The company’s stock was down 0.6% on Tuesday. So far this year, AbbVie’s stock is down 2.7%, shares of Humanigen hav soared 410.9%, and the S&P 500 is up 9.4%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.